XTSXEKG
Market cap3mUSD
Oct 20, Last price
0.03CAD
Name
CardioComm Solutions Inc
Chart & Performance
Profile
CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company's technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its proprietary device connectivity and ECG management technologies are used in medical, consumer, clinical research, and telemedicine solutions. The company's software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders, as well as HeartCheck CardiBeat. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring. Additionally, the company provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 876 -11.99% | 996 45.90% | 683 -18.24% | |||||||
Cost of revenue | 991 | 879 | 866 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (114) | 116 | (183) | |||||||
NOPBT Margin | 11.69% | |||||||||
Operating Taxes | 98 | 298 | ||||||||
Tax Rate | 84.13% | |||||||||
NOPAT | (114) | 18 | (482) | |||||||
Net income | (97) 3,864.40% | (2) -967.49% | 283 -100.44% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 25 | |||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 438 | 345 | 417 | |||||||
Long-term debt | 124 | 20 | 59 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 471 | 308 | 367 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (54) | 55 | (121) | |||||||
CAPEX | (10) | (3) | ||||||||
Cash from investing activities | (10) | (3) | ||||||||
Cash from financing activities | 91 | (96) | 109 | |||||||
FCF | (156) | 95 | (860) | |||||||
Balance | ||||||||||
Cash | 91 | 56 | 108 | |||||||
Long term investments | ||||||||||
Excess cash | 47 | 7 | 73 | |||||||
Stockholders' equity | (654) | (569) | (602) | |||||||
Invested Capital | 639 | 507 | 602 | |||||||
ROIC | 3.33% | |||||||||
ROCE | 743.99% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 151,146 | 150,820 | 149,152 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (90) | 145 | (155) | |||||||
EV/EBITDA | ||||||||||
Interest | 29 | 23 | 32 | |||||||
Interest/NOPBT | 19.83% |